Vivanza Biosciences Current Share Price | Vivanza Biosciences Stock Screener
VIVANZA
Pharmaceuticals
Vivanza Biosciences Current Stock Price Today
Live Share Price BSE
₹1.76
▼
-0.04 (-2.22%)
As of September 18, 2026, the live Vivanza Biosciences share price (BSE: VIVANZA) is ₹1.76, down 2.22% from the previous close, with shares trading between ₹1.76 and ₹1.80 in today's trading session, and a 52-week range of ₹1.70–₹2.61.
Browse VIVANZA annual financials to support your investment research.
Use the Vivanza Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Vivanza Biosciences Market Cap
₹7.54 Cr.
VIVANZA P/E Ratio (TTM)
17.09
Vivanza Biosciences P/B Ratio
1.73
EPS (TTM)
₹0.10
Dividend Yield
-
Debt to Equity
2.26
VIVANZA 52 Week High
₹2.61
Vivanza Biosciences 52 Week Low
₹1.70
Operating Margin
-1.00%
Profit Margin
-
VIVANZA Revenue (TTM)
₹10.00
EBITDA
-
Net Income
-
Total Assets
₹22.00
Total Equity
₹4.00
Vivanza Biosciences Current Share Price Chart
Track the current Vivanza Biosciences share price and stock price with an interactive chart. Analyse VIVANZA price trends, trading volume, historical performance, and volatility across different timeframes — the complete Vivanza Biosciences stock quote in one place.
Vivanza Biosciences Company Profile - Fundamental Screener
Screen Vivanza Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VIVANZA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE984E01035
Vivanza Biosciences Balance Sheet Screener
Screen VIVANZA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 22 | 17 | 20 | 23 | 16 | 8 | 12 | 11 | 10 | 7 |
| Current Assets | 19 | 12 | 16 | 20 | 13 | 5 | 9 | 8 | 7 | 4 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 3 | 3 | 1 | 3 | 0 | 0 | 1 | 1 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 4 | 4 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 0 | 0 | 1 | 0 | -1 | -1 | -1 | -1 | 0 | -1 |
Vivanza Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Vivanza Biosciences income statement and profit fundamentals.
Analyze VIVANZA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Vivanza Biosciences share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 6 | 45 | 55 | 9 | 1 | 2 | 3 | 2 | 4 | 7 | 8 | 9 | 8 | 6 |
| Expenses | 9 | 7 | 45 | 55 | 9 | 1 | 1 | 3 | 2 | 5 | 6 | 7 | 9 | 8 | 5 |
| EBITDA | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Operating Profit % | -1.00% | -4.00% | 0.00% | 1.00% | 2.00% | -200.00% | 8.00% | 4.00% | 15.00% | -3.00% | 4.00% | 4.00% | 6.00% | 0.00% | 10.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| EPS | 0.04 | -0.11 | 0.05 | 0.14 | 0.02 | -0.25 | 0.01 | 0.00 | 0.07 | -0.10 | 0.05 | 0.07 | 0.12 | -0.26 | 1.15 |
Vivanza Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen VIVANZA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -3 | -3 | 2 | -1 | 3 | -3 | 3 | 1 | 0 | -2 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Financing Activities | 3 | 3 | -2 | 1 | -3 | 3 | -3 | -1 | -1 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
Vivanza Biosciences Shareholding Pattern Screener
See Vivanza Biosciences shareholding pattern with promoter, FII, and DII holdings.
Check Vivanza Biosciences promoter holding and ownership changes for VIVANZA on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 39.86% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 73.49% | 73.34% | 73.42% | 73.34% | 73.36% | 73.69% | 71.21% | 51.05% |
| Other Holding | 6.49% | 6.64% | 6.56% | 6.64% | 6.62% | 6.29% | 8.77% | 9.09% |
| Shareholder Count | 19,254 | 19,461 | 19,822 | 20,170 | 20,458 | 20,833 | 20,635 | 16,701 |
Vivanza Biosciences Share Dividend Screener - Share Yield Analysis
Check Vivanza Biosciences dividend history with payout and yield data.
View Vivanza Biosciences dividend details including ex-dates and amounts for VIVANZA stock.
Vivanza Biosciences Stock Index Membership
See which indices include Vivanza Biosciences stock.
Check VIVANZA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Vivanza Biosciences Market Events Screener - Corporate Actions
Get Vivanza Biosciences corporate actions including splits, bonuses, and buybacks.
Check Vivanza Biosciences stock events that may affect VIVANZA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-11 | 2026-09-11 | Annual General Meeting | NA | 6.21% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 4.42% |
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | -2.44% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 2.44% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 0.51% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -0.48% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 2.45% |
| 2025-05-12 | 2025-05-12 | Quarterly Result Announcement | NA | -4.59% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -2.93% |
| 2024-10-17 | 2024-10-17 | Quarterly Result Announcement | NA | -6.39% |
| 2024-08-01 | 2024-08-01 | Annual General Meeting | NA | -4.19% |
| 2023-03-24 | 2023-03-24 | Split | 1:10 | 34.08% |
| 2022-07-21 | 2022-07-21 | Annual General Meeting | NA | 3.17% |
Vivanza Biosciences Competitors Screener - Peer Comparison
Screen VIVANZA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Vivanza Biosciences Company Announcements - News Screener
Screen VIVANZA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-19 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-18 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-18 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-20 | Announcement Under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-19 | Reg. 34 (1) Annual Report. | - |
| 2026-08-19 | Notice Of The 44Th Annual General Meeting (AGM) And Annual Report Of The Company For The Financial Year 2025-26 | - |
| 2026-08-17 | Board Meeting Outcome for Outcome Of Board Meeting Held On 17.08.2026 | - |
| 2026-08-12 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1)(A) And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-08 | Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI LODR Regulations 2015 | - |
| 2026-08-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited (The Company) | - |
| 2026-08-07 | Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited (The Company) | - |
| 2026-08-07 | Board Meeting Outcome for Outcome Of Board Meeting To Consider And Approve Unaudited Financial Results (Standalone And Consolidated) For Quarter Ended 30Th June 2026 | - |
| 2026-07-31 | Update on board meeting | - |
| 2026-07-28 | Board Meeting Intimation for The Consideration And Approval Of The Quarterly Financial Result Ended On 30Th June 2026. | - |
| 2026-07-14 | Declaration Pursuant To Regulation 33(3)(D) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-07-09 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-07-09 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 09Th July 2026. | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-29 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |